These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32988154)

  • 1. [Analysis of EGFR mutation and clinical features of lung cancer in Yunnan].
    Zhou YC; Lin YP; Li Q; Ma LY; Liu X; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Dai M; Zhang Q
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):729-734. PubMed ID: 32988154
    [No Abstract]   [Full Text] [Related]  

  • 2. Survival analysis of patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment of Yunnan in southwestern China: a real-world study.
    Lin Y; Chen L; Li R; Liu X; Li Q; Cai J; Du Y; Zhao G; Wang X; Shen Z; Liao Y; Chen Y; Xie L; Zhou Y; Huang Y
    Front Oncol; 2023; 13():1156647. PubMed ID: 37881485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
    Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155
    [No Abstract]   [Full Text] [Related]  

  • 4. Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China.
    Zhou Y; Yang Y; Yang C; Chen Y; Yang C; Du Y; Zhao G; Guo Y; Ye L; Huang Y
    Oncotarget; 2017 Feb; 8(9):15023-15033. PubMed ID: 28107191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.
    Chiu CH; Yang CT; Shih JY; Huang MS; Su WC; Lai RS; Wang CC; Hsiao SH; Lin YC; Ho CL; Hsia TC; Wu MF; Lai CL; Lee KY; Lin CB; Yu-Wung Yeh D; Chuang CY; Chang FK; Tsai CM; Perng RP; Chih-Hsin Yang J
    J Thorac Oncol; 2015 May; 10(5):793-799. PubMed ID: 25668120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
    Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique characteristics of G719X and S768I compound double mutations of epidermal growth factor receptor (EGFR) gene in lung cancer of coal-producing areas of East Yunnan in Southwestern China.
    Wang JL; Fu YD; Gao YH; Li XP; Xiong Q; Li R; Hou B; Huang RS; Wang JF; Zhang JK; Lv JL; Zhang C; Li HW
    Genes Environ; 2022 May; 44(1):17. PubMed ID: 35606799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mutation status of epidermal growth factor receptor and KRAS gene in non-small cell lung cancers at Xuanwei regions of Yunnan Province].
    Yang CS; Pan XY; Feng Q; Wang YY; Xu WM; Jiang T; Wang L; Yang JL; Wang L
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):226-30. PubMed ID: 27033384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct
    Lv L; Liu Z; Liu Y; Zhang W; Jiang L; Li T; Lu X; Lei X; Liang W; Lin J
    Front Oncol; 2020; 10():519073. PubMed ID: 33224870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features.
    Lai Y; Zhang Z; Li J; Sun D; Zhou Y; Jiang T; Han Y; Huang L; Zhu Y; Li X; Yan X
    Int J Mol Sci; 2013 Dec; 14(12):24549-59. PubMed ID: 24351833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I.
    Pang LL; Gan JD; Tan JR; Huang YH; Liao J; Liang WT; Deng PB; Fang WF
    Cancer; 2022 Nov; 128(21):3804-3814. PubMed ID: 36069292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.
    Xu J; Jin B; Chu T; Dong X; Yang H; Zhang Y; Wu D; Lou Y; Zhang X; Wang H; Han B
    Lung Cancer; 2016 Jun; 96():87-92. PubMed ID: 27133756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma with the Rare Epidermal Growth Factor Receptor Mutation S768I: a Retrospective Analysis and Literature Review.
    Zhu X; Bai Q; Lu Y; Qi P; Ding J; Wang J; Zhou X
    Target Oncol; 2017 Feb; 12(1):81-88. PubMed ID: 27538584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uygur and Han ethnic groups.
    Zhang Y; Wang Q; Han ZG; Shan L
    Asian Pac J Cancer Prev; 2013; 14(5):2879-83. PubMed ID: 23803047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?
    Banno E; Togashi Y; Nakamura Y; Chiba M; Kobayashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Mitsudomi T; Nishio K
    Cancer Sci; 2016 Aug; 107(8):1134-40. PubMed ID: 27240419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of epidermal growth factor receptor mutations and its clinico-pathologic characteristics of the primary lung adenocarcinoma in Xinjiang Uighur Autonomous Region].
    Ma XM; Cao YZ; Ji WL; Zhao F; Fang XZ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):663-666. PubMed ID: 29263509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan.
    Hsu PC; Lee SH; Chiu LC; Lee CS; Wu CE; Kuo SC; Ju JS; Huang AC; Li SH; Ko HW; Yang CT; Wang CC
    Target Oncol; 2023 Mar; 18(2):195-207. PubMed ID: 36805452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful Treatment of a Patient with Lung Adenocarcinoma Harboring Compound EGFR Gene Mutations, G719X and S768I, with Afatinib.
    Kutsuzawa N; Takahashi F; Tomomatsu K; Obayashi S; Takeuchi T; Takihara T; Hayama N; Oguma T; Aoki T; Asano K
    Tokai J Exp Clin Med; 2020 Sep; 45(3):113-116. PubMed ID: 32901897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational characteristics of Chinese Han and ethnic minorities in southwestern China: a propensity score matched analysis.
    Zhou Y; Liu X; Guo Y; Li Z; Zhu S; Li Q; Wang X; Yang R; Shen Z; Li H; Du Y; Ma L; Shen S; Lan Y; Huang Y
    Ann Transl Med; 2022 Jul; 10(14):782. PubMed ID: 35965830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-Generation Sequencing Reveals High Uncommon EGFR Mutations and Tumour Mutation Burden in a Subgroup of Lung Cancer Patients.
    Guo G; Li G; Liu Y; Li H; Guo Q; Liu J; Yang X; Shou T; Shi Y
    Front Oncol; 2021; 11():621422. PubMed ID: 33889543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.